These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11906669)

  • 1. Quality control of leucoreduced cellular blood components in France.
    Chabanel A; Andreu G; Carrat F; Hervé P
    Vox Sang; 2002 Feb; 82(2):67-71. PubMed ID: 11906669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National French observatory of the quality of blood components for transfusion.
    Chabanel A; Masse M; Begue S;
    Transfus Clin Biol; 2008 Jun; 15(3):85-90. PubMed ID: 18524661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of leucoreduced red blood cell concentrates: 5 years of follow-up in France.
    Chabanel A; Carrat F; Begue S; Masse M; Perrault MP; Andreu G
    Vox Sang; 2008 Jan; 94(1):41-7. PubMed ID: 18171328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
    Dumont LJ
    Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
    [No Abstract]   [Full Text] [Related]  

  • 5. Leukodepleted blood components: definition of a standard.
    Andreu G; Masse M; Royer SD; Tardivel R
    Transfus Sci; 1998 Dec; 19(4):381-3. PubMed ID: 10351163
    [No Abstract]   [Full Text] [Related]  

  • 6. Value of central analysis of leucocyte depletion quality control data within the National Blood Service, England.
    Beckman N; Cardigan R; Wallington T; Williamson LM
    Vox Sang; 2002 Aug; 83(2):110-8. PubMed ID: 12201840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP).
    Chamfly V
    Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148
    [No Abstract]   [Full Text] [Related]  

  • 8. International views on universal leucodepletion: the perspective in The Netherlands.
    de Wit HC
    Transfus Sci; 1998 Dec; 19(4):353-4. PubMed ID: 10351153
    [No Abstract]   [Full Text] [Related]  

  • 9. Quality control of leucocyte-reduced blood components: overestimation of WBC content due to nucleated red blood cells.
    Fischer JC; Moog R; Giers G
    Vox Sang; 2012 Jan; 102(1):79-81. PubMed ID: 21564108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT).
    Dumont LJ; Dzik WH; Rebulla P; Brandwein H
    Transfusion; 1996 Jan; 36(1):11-20. PubMed ID: 8607148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International views on universal leucodepletion: the perspective in Germany.
    Seitz MD
    Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155
    [No Abstract]   [Full Text] [Related]  

  • 12. [Quality control management. Application to the production of unstable blood components].
    Masse M
    Rev Fr Transfus Immunohematol; 1988 Dec; 31(5):747-56. PubMed ID: 3070708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Logistical problems of supplying leucodepleted blood components within the national blood service.
    Tandy N
    Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160
    [No Abstract]   [Full Text] [Related]  

  • 14. Universal leucodepletion--practical and regulatory consequences.
    Barrowcliffe TW
    Transfus Sci; 1998 Dec; 19(4):361. PubMed ID: 10351156
    [No Abstract]   [Full Text] [Related]  

  • 15. New approach to 'top-and-bottom' whole blood separation using the multiunit TACSI WB system: quality of blood components.
    Lotens A; Najdovski T; Cellier N; Ernotte B; Lambermont M; Rapaille A
    Vox Sang; 2014 Oct; 107(3):261-8. PubMed ID: 24861237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing effective working partnership with manufacturers.
    Pujol-Reyz A
    Transfus Sci; 1998 Dec; 19(4):375-6. PubMed ID: 10351161
    [No Abstract]   [Full Text] [Related]  

  • 17. International views on universal leucodepletion: the perspective in NBS, England.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
    [No Abstract]   [Full Text] [Related]  

  • 18. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies.
    Seghatchian MJ; Krailadsiri P
    Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157
    [No Abstract]   [Full Text] [Related]  

  • 19. International views on universal leucodepletion: the perspective in Portugal.
    de Sousa G
    Transfus Sci; 1998 Dec; 19(4):351-2. PubMed ID: 10351152
    [No Abstract]   [Full Text] [Related]  

  • 20. Operational and research approaches to universal leucodepletion in Scotland.
    Prowse C
    Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.